Dec. 3 at 11:08 PM
$SPRY $MIRM
NEFFY had a massive showing at the Piper Sandler conference. Adoption is taking off with over 20,000 prescribers and the count doubling in the last three months. Doctors trying it keep using it, and real-world data now shows it works the same as injectable epinephrine, which removes the last hesitation.
Awareness has jumped from under 20 percent to over 50 percent thanks to TV and digital campaigns. The GET NEFFY program is a major catalyst with zero copay, zero virtual visit cost, fast online approval, and doctors using it to bypass prior authorizations. This removes almost all friction for switching.
Coverage is improving fast. Optum and Express Scripts are on board, Blue Cross plans are coming in gradually, and eight Medicaid states already list NEFFY as preferred. As coverage expands, adoption expands.
Real-world performance is strong: Japan Phase 3 showed 100 percent response, and the U.S. experience program (680+ patients) showed the classic 90 percent one-dose response seen with injections. NEFFY is now fully validated clinically and practically.
NEFFY is also growing the market. About 80 percent of prescriptions are switchers, but 20 percent are new patients who either never filled an autoinjector or never had epinephrine at all. This taps into the huge underserved group of people who should be carrying epinephrine but aren’t.
Needle-free delivery also opens doors for airlines, schools, restaurants, and first responders who avoided autoinjectors due to liability. This institutional channel could be a major tailwind.
International pricing is excellent. Europe and Canada come in at more than twice EpiPen pricing, Japan’s net price is higher than the U.S., and more regions are expected to approve in 2026. Germany, which has no payer barriers, is seeing strong market share growth — a preview of U.S. adoption as friction continues to fall.
Competition isn’t viewed as a threat. The market is massively underpenetrated, and new entrants would likely grow the category rather than hurt NEFFY.
On top of that, CSU is emerging as a second major opportunity. NEFFY showed rapid itch reduction in five minutes, Phase 2b is underway with a lower dose, and Phase 3 is expected to start at the end of 2025. This could become a blockbuster second indication.
Bottom line: NEFFY is scaling fast, expanding the market, winning with patients and doctors, gaining payer support, growing internationally, opening institutional demand, and adding a second major pipeline indication. Everything is lined up for a strong 2025 and 2026.
